GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Short Percentage of Float

BriaCell Therapeutics (TSX:BCT) Short Percentage of Float


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of BriaCell Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, BriaCell Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Short Percentage of Float falls into.


;
;

BriaCell Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Short Percentage of Float
Comparable Companies
XCNQ:PHRM XCNQ:TELI XCNQ:MDMA XCNQ:DOSE TSXV:SBM XCNQ:PREV TSXV:KNE TSX:CSCI XCNQ:BIOV TSXV:HEM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
BCTX:USA 8BT0:Germany
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
Website
https://www.briacell.com
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Jamieson Bondarenko Director
Marc Lustig 10% Security Holder, Director
Gadi Levin Senior Officer
William Williams Director, Senior Officer

BriaCell Therapeutics Headlines

No Headlines